Pulmatrix, Inc. (PULM) Stock Score, Valuation & Financial Research

Pulmatrix, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for PULM

Pulmatrix, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.37. These figures are a research snapshot, not a buy or sell recommendation.

What Pulmatrix, Inc. does

Pulmatrix, Inc. (PULM) is a clinical-stage biotechnology firm focused on creating and advancing inhaled treatments. The company's primary goal is to address significant unmet medical needs in respiratory and other diseases within the United States. Central to their approach is the innovative iSPERSE (inhaled small particles easily respirable and emitted) technology. This proprietary platform allows for the precise delivery of both small and large molecule therapeutics directly into the lungs, achieving either localized effects or systemic distribution throughout the body. Pulmatrix's development pipeline includes several key candidates: Pulmazole: An inhaled antifungal drug being developed to treat allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis. PUR1800: A narrow spectrum kinase inhibitor currently undergoing Phase 1b clinical trials for individuals suffering from stable moderate-to-severe chronic obstructive pulmonary disease (COPD). PUR3100: An iSPERSE-formulated version of dihydroergotamine, intended for the rapid relief of acute migraine attacks. The company also maintains strategic collaborations, including a licensing arrangement with RespiVert Ltd. for access to a range of kinase inhibitor drug candidates, a partnership with Cipla Technologies LLC for the development and commercialization of Pulmazole, and a collaboration and license agreement with Sensory Cloud, Inc. Established in 2003, Pulmatrix, Inc. is headquartered in Lexington, Massachusetts.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Pulmatrix is a clinical-stage biopharmaceutical company that focuses on the development of inhaled therapeutic products. Its business model relies on the research and development of proprietary drug candidates using its iSPERSE technology, with the intent to monetize these assets through licensing agreements, strategic partnerships, or future commercialization of its pipeline.

Products and services

  • The company develops inhaled therapeutic products for respiratory and CNS diseases using its proprietary iSPERSE dry powder delivery platform.

Brands and product families

  • iSPERSE — Proprietary engineered dry powder delivery platform. Source

Customer types

Pharmaceutical and biotechnology companies.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials. Source

Business relationships and partnerships

  • MannKind Corporation — In July 2024, MannKind acquired an exclusive license to the Pulmatrix iSPERSE formulation. Source

Business strengths to evaluate

  • Proprietary iSPERSE dry powder delivery platform Source

Business risks and research considerations

  • History of operating losses and dependence on additional financing Source
  • Reliance on third-party manufacturers and clinical research organizations Source

Sources: Company research source · MannKind Corporation

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

PULM financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 1.37
Market capitalization:
5M (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -4.01M
Free cash flow:
USD -5.43M
Cash:
USD 2.17M
Total debt:
USD 0.00
EPS:
USD -1.10

What stands out

  • Free cash flow is USD -5.43M, negative for the stored period.
  • The balance sheet shows USD 2.17M of cash versus USD 0.00 of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a missing revenue history warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 2.17M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for PULM

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can PULM fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is PULM likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for PULM to reach sustainable profitability?
  • What does the current missing revenue history warning mean for the reliability or interpretation of PULM's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-15.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research PULM

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.